Drug Profile
GSK 356278
Alternative Names: GSK356278Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antidepressants; Anxiolytics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anxiety disorders; Huntington's disease; Major depressive disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Huntington's-disease(In volunteers) in Netherlands (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Huntington's-disease(In volunteers) in United Kingdom (PO)
- 15 Mar 2012 No development reported - Phase-I for Anxiety disorders in Australia (PO)